Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | PI4KA | P42356 | 2/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | XDH | P47989 | 1/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL2564210 | 0.85 | PI4KA (0.55) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL22748487 | 0.85 | PI4KA (0.55) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL15700 | 0.85 | PI4KA (0.55) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL8414755 | 0.85 | PI4KA (0.51) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL9621210 | 0.85 | PI4KA (0.81) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL23531102 | 0.84 | PI4KA (0.54) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL11807683 | 0.84 | PI4KA (0.54) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL1324561 | 0.84 | PI4KA (0.54) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL27518288 | 0.84 | PI4KA (0.54) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL7712108 | 0.84 | PI4KA (0.54) | LMNAPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | UNIV OREGON HEALTH & SCIENCE (US) | 2023-07-06 | — | — | US | claimed |
| WO-2021262548-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-12-30 | — | — | WO | claimed |
| US-20180258464-A1 | METHODS FOR THE DESIGN OF MECHANISM-BASED SIRTUIN ACTIVATING COMPOUNDS | CHAKRABARTI ADVANCED TECHNOLOGY LLC | 2018-09-13 | — | — | US | claimed |
| WO-2017048836-A1 | METHODS FOR THE DESIGN OF MECHANISM-BASED SIRTUIN ACTIVATING COMPOUNDS | PMC ADVANCED TECHNOLOGY LLC (US) | 2017-03-23 | — | — | WO | claimed |
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | claimed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | claimed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | claimed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | claimed |
| EP-4370125-A1 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | Oregon Health and Science University (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024013349-A1 | BENZAMIDE ADENINE DINUCLEOSIDE COMPOUNDS AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013349-A1 | BENZAMIDE ADENINE DINUCLEOSIDE COMPOUNDS AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-01-18 | — | — | WO | disclosed |
| US-11834470-B2 | 4-thioribose NAD analogues and methods of synthesizing and using the same | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | UNIV OREGON HEALTH & SCIENCE (US) | 2023-07-06 | — | — | US | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| EP-1349562-A2 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY | Duke University (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030148966-A1 | Method and composition for inducing apoptosis in cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE OF INDIANA UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| US-20020128205-A1 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | DUKE UNIVERSITY OFFICE OF SCIENCE AND TECHNOLOGY (US) | 2002-09-12 | — | — | US | disclosed |
| WO-2002055018-A2 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY | DUKE UNIVERSITY (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
| US-5902792-A | Method of inducing apoptosis in cancer cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1999-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834470-B2 | 4-thioribose NAD analogues and methods of synthesizing and using the same | CD38, NQO1, NADK | LMNA 2720/4885PI4KA 3664/4885PI4K2B 3669/4885 |
| US-20020128205-A1 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | GGH, GSS, GSR | LMNA 4362/4885PI4KA 4247/4885PI4K2B 4529/4885 |
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | SARM1, PARP16, NAMPT | LMNA 992/4885PI4KA 3648/4885PI4K2B 3024/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | LMNA 871/4885PI4KA 3474/4885PI4K2B 3871/4885 |
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | LMNA 4363/4885PI4KA 672/4885PI4K2B 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.